Priority:



NHS Number:

(Including Prostate, Bladder, Renal, Testicular & Penile) SCR Referral for all patients over the age of 16 years

**Priority**Referral Date:

Sho	rt date letter merged	NHS Number				
Pati	ient Details / Contact Info	ormation				
Title:	•	Forename:	Surname:			
Title	2	Surname				
Date	of Birth:	Given Name Gender:	Ethnicity:			
	e of Birth	Gender(full)				
Addr		Home Telephone Number:	Ethnic Origin			
	ne Full Address (stacked)	Patient Home Telephone	Patient E-mail Add	dress		
	Status:	OR Mobile Telephone Number:	Text Message Cons			
041.01		Patient Mobile Telephone	Yes No	]		
Prefe	rred Contact Time:	Interpreter Required:	Preferred Language	(spoken):		
		Yes No	Single Code Entry: Main spoken			
			language	y. Main spoken		
		Single Code Entry: Interpreter not				
		needed	Preferred Language	(written):		
D-f	aman / Duastica Dataila					
	errer / Practice Details					
	ring Name:	Referrer Code:	Practice Code:			
Cur	rent User		Registered GP Organisation National			
			Practice Code			
	tered GP:	Surgery Name:	Surgery Address:			
Reg	istered GP Full Name	Registered GP Organisation Name	Registered GP Full	Address (sta	acked)	
	ery Telephone Number:	Generic Surgery Email Address:				
Org	anisation Telephone Number	Organisation E-mail Address				
N/a-	adatam. Information	Il be not one od if not complete				
	<u>-</u>	ll be returned if not complete				
		rior to having an appointment or during thei		t is therefore	?	
impo	rtant that patients are prepared for	r this and aware of the reason for their refer	ral.	.,		
4				Yes	No	
1.	•	y are on a suspected cancer pathway, given a	ippropriate support			
	·	ble at any time within the next two weeks?				
	If no, please explain why:					
2. Can the patient be contacted by telephone?						
	If yes, and the number is different from above, please enter here:					
	Landline Number:					
	OR Mobile Number:					
	If NO, why and what is the					
	preferred method of					
	contact?					
3.	Can the patient be contacted by le	tter?				
Page 1	of F					

Date Created: September 2020 Date Reviewed: September 2023 Next Review due: September 2024



(Including Prostate, Bladder, Renal, Testicular & Penile) SCR Referral for all patients over the age of 16 years

	Please expand below, if GP Practice", etc.				
4.	Have you told your patient they may have appointments and tests arranged at any hospital across Greater Manchester? Initial appointments are still likely to be at your local trusts.				
5.	Accurate functional status is needed to assess the most appropriate investigation and treatment.  Please select a score from one of the following and enter in the score field:				
	Rockwood Score 1-3 Managing Well. Not limited by any comorbidities		1		
	Rockwood Score 4 Vulnerable, not dependant, symptoms limit activities		Score:		
	Rockwood Score 5	Mildly frail, evident slowing, need help with daily activities	Single Code		
	Rockwood Score 6	Moderately frail, need help with all outside activities and bathing	Entry: Rockwood		
	Rockwood Score 7-8	Severely frail, completely dependent for personal care	Clinical Fr	ailty	
	Rockwood Score 9	Terminally ill, life expectancy of <6 months	Scale scor	e	
6.	Are there any concerns a	bout this patient's capability to consent to investigation/treatment?			
	If Yes, has the next of kir	n/advocate been asked to attend?			
7.	Is the patient taking anti	-coagulants?			
	If Yes please give details				
8.	Is the patient diabetic ar				
	If Yes please give details				
9.			Value:		
10.	Current eGFR of patient:  Recent changes to guidance mean eGFR is no longer required in all patients.  If the value is not appearing this has not been recorded in the last 3 months, therefore has the eGFR been requested today in patients:  - with known renal disease (CKD 3/4/5 or renal transplant)  - who are diabetic  - who are on metformin		Single Code Entry: GFR (glomerular filtration rate) calculated by abbreviated Modification of Diet in Renal Disease Study Group calculation  Yes No		
10.	If Yes, which language:				
11.	Does the patient have ar physical/learning disabil	ny other health conditions, impairments or access requirements that may red ty):	quire support	:? (e.g.	
	ferral Reason (	include relevant family history, previous history of ca	ncer and	all	



(Including Prostate, Bladder, Renal, Testicular & Penile) SCR Referral for all patients over the age of 16 years

## **Referral Information**

#### **PROSTATE CANCER**

Patient information leaflet

<u>Prostate Patient Information - Greater Manchester Cancer (gmcancer.org.uk)</u>

Ensure that all available PSA values are included in this referral.				
Consider the impact of referring patients with significant co-morbidity and the very frail elderly as referral m	ay not be			
appropriate. If in doubt consult your local specialist.				
<ul> <li>Hard irregular prostate on DRE (please specify side)</li> </ul>	LEFT	RIGHT		
Raised age-related PSA UTI having been excluded	YES	NO		
<ul> <li>Information regarding PSA testing:         <ul> <li>PSA can be markedly raised in a UTI and should avoided in this scenario</li> <li>If there are any sign of advanced or metastatic prostate cancer a suspected cancer referral is still incomposition of a UTI</li> <li>Following a UTI it can take up to six weeks or more for the PSA to normalise</li> <li>Rectal examination and exercise have minimal effect on PSA and should not affect the timing of test</li> <li>Ejaculation only has a minor impact on PSA results but it is best avoided for 48 hours</li> </ul> </li> </ul>		pective		
Age related cut-off measurements for PSA: <49 years: refer if PSA level is 2.0 nanogram/mL or higher				
50–59 years: refer if PSA level is 3.0 nanogram/mL or higher				
60–69 years: refer if PSA level is 4.0 nanogram/mL or higher				
70–74 years: refer if PSA level is 5.0 nanogram/mL or higher				
75–80 years: refer if PSA level is 7.5 nanogram/ml or higher				
>80 years: Men aged 80 years and over can be referred for assessment but there is no stipulated range to necessarily trigger a 2 week wait other than Clinician discretion				
NHSE is considering reviewing PSA referral criteria. Currently the GM Cancer Alliance is using the age specific PSA levels above.				
PSA Result (latest): Single Code Entry: PSA (prostate-specific antigen) level				
BLADDER AND RENAL CANCER (age 45 and above)	YES	NO		
Unexplained visible haematuria and no UTI				
<ul> <li>Visible haematuria that persists or recurs after successful treatment of UTI</li> </ul>				
BLADDER CANCER (age 60 and above)	YES	NO		
<ul> <li>Unexplained non-visible haematuria PLUS either:</li> </ul>				
■ Dysuria				
Raised white cell count on blood test				



NO

YES

(Including Prostate, Bladder, Renal, Testicular & Penile) SCR Referral for all patients over the age of 16 years

#### **TESTICULAR CANCER**

Review the GM Cancer Scrotal Lump Evaluation document: Testicular-Lump-Evaluation.pdf (gmcancer.org.uk)

<ul> <li>Non painful enlargement or change in shape or texture of testis</li> </ul>		
<ul> <li>Suspected testicular cancer on USS report (report attached)</li> </ul>		
PENILE CANCER	YES	NO
PENILE CANCER  Penile mass or ulcerated lesion where STD is thought to be unlikely or excluded as cause	YES	NO
	YES	NO

#### **HAEMATURIA**

- Refer patients under 45 with visible haematuria for non-urgent investigation.
- Refer patients with persistent non-visible haematuria for non-urgent investigation.
- Consider prostate cancer via DRE and PSA.

### **Consultations**

Consultations

## **Pathology**

_	<b>0</b> 7				
Sodium	Single Code Entry: Serum sodium level	Total Chol.	Single Code Entry: Serum total cholesterol	wcc	Single Code Entry: Total white cell count
			level		
Potassium	Single Code Entry: Serum potassium level	LDL Chol.	Single Code Entry: Serum low density	Plat	Single Code Entry: Platelet count
			lipoprotein cholesterol level		
Urea	Single Code Entry: Serum urea level	HDL Chol.	Single Code Entry: Serum high density	MCV	Single Code Entry: MCV - Mean
			lipoprotein cholesterol level		corpuscular volume
Creatinine	Single Code Entry: Serum creatinine level	Folate	Single Code Entry: Serum folate level	Ferritin	Single Code Entry: Serum ferritin level
eGFR	Single Code Entry: Glomerular filtration	Bilirubin	Single Code Entry: Serum bilirubin level		
	rate				

## Haematology

Haemoglobin: Haemoglobin

Haemoglobin estimation: Single Code Entry: Haemoglobin estimation

ALT: ALT

**Blood Glucose:** Blood Glucose **Alkaline Phosphatase:** Alkaline Phosphatase

Radiology

Radiology: Radiology

### **Diabetic Control**

**HbA1c:** HbA1c

Page **4** of **5** 

Date Created: September 2020 Date Reviewed: September 2023 Next Review due: September 2024



(Including Prostate, Bladder, Renal, Testicular & Penile)
SCR Referral for all patients over the age of 16 years

## **Thyroid Function (if applicable)**

T4 / TSH Test (to ensure this is not repeated unnecessarily in secondary care)				
T4:	Single Code Entry: Serum free T4 level	TSH: stimulatii	Single Code Entry: Serum TSH (thyroid ng hormone) level	

### **Health Profile**

Problems
Medication
Allergies
Family History
Alcohol Consumption

Smoking Weight Height BMI

**Blood Pressure** 

## **Long Term Conditions**

IHD: Single Code Entry: Aortocoronary artery bypass graft repeated...

Diabetes: Single Code Entry: Diabetes mellitus without complication...

Single Code Entry: Diabetes mellitus type 1 with ketoacidotic coma...

**Hypertension:** Single Code Entry: Hypertensive disease...

**Epilepsy:** Single Code Entry: Recurrent complex partial epilepsy... **Stroke/TIA:** Single Code Entry: Anterior cerebral artery syndrome...

**Parkinson's:** Single Code Entry: Parkinson's disease...

Dementia: Single Code Entry: Circumscribed cerebral atrophy...
 COPD: Single Code Entry: Acute vesicular emphysema...
 CKD: Single Code Entry: Chronic kidney disease stage 4...

**Neoplasms:** Single Code Entry: [X]Additional neoplasm classification terms...

Single Code Entry: Neuroblastoma of central nervous system...

## Contraception

FOR FEMALE PATIENTS ONLY

(please check medication screen for items that may not have filtered through)

Single Code Entry: Prescribed postcoital oral contraceptive pill...

Page 5 of 5

Date Created: September 2020 Date Reviewed: September 2023 Next Review due: September 2024